Skip to main content
. 2021 Aug 29;10(1):1958590. doi: 10.1080/2162402X.2021.1958590

Figure 2.

Figure 2.

Internalization of WT avelumab compared with its anti–PD-L1 binding–deficient variant (R99K) and FcγR binding–deficient variant (N297A) in total human monocytes and granulocytes. Internalization in (a) total monocytes and (b) granulocytes from a representative donor is shown. Results were similar in other donors (data not shown). Error bars represent standard deviations of replicate assays from the same donor. Anti–PD-L1, anti–programmed death ligand 1; WT, wild-type